A COVID-19 rapid antibody test, developed by York-based Abingdon Health, has been approved for professional use in the UK and EU.
Securing CE mark means the rapid test – for detection of IgG antibodies to the SARS-CoV-2 virus (COVID-19) – is now available for distribution for professional use.
It will be mass produced and tests will be rolled out from the end of August. The test can be administered by healthcare professionals, such as doctors, nurses, pharmacists and healthcare workers.
Following production of tens of thousands of tests across multiple production scale batches the test has been shown to be 99.40% accurate. Testing was performed at the Ulster University and at the laboratories of Abingdon Health.
The test, which will be named the ‘AbC-19TM Rapid Test’, uses a small drop of blood from a finger-prick, and shows results in 20 minutes, without the need to send a sample to a lab.
Abingdon Health will begin to manufacture and ramp up production in August. The firm will produce 500,000 COVID-19 antibody tests a month from October and one million a month from January 2021.
“This UK designed, developed and manufactured high-quality rapid diagnostic test is a breakthrough for UK life sciences and a triumph of British business,” said Abingdon Health CEO Chris Yates.
“It has been a company-wide effort at Abingdon Health to achieve this milestone in such a short space of time. Our research and development teams have been working two shifts a day, seven days a week, to develop the test. We have deployed nearly fifteen times the number of people that would be on a typical project to deliver this test as quickly as possible.”